MMP9 and metastatic neoplasm: Based on the negative impact of anti‐MMP9 antibody in the pre‐clinical PDAC models in terms of tumour stroma, metastasis and EMT, our data support the possible advantages of anti‐MMP9 antibody therapy in PDAC patients with localized non‐metastatic disease.